共 54 条
[1]
Slamon DJ(2001)Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2 N Engl J Med 344 783-792
[2]
Leyland-Jones B(2007)Ratio of trastuzumab in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anti-Cancer Drug 18 23-28
[3]
Shak S(2006)Lapatinib plus capecitabine for HER-2 positive advanced breast cancer N Engl J Med 355 2733-2743
[4]
Stemmler HJ(2004)Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer Br J Cancer 91 639-643
[5]
Schmitt M(2007)Central nervous system metastases in HER2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors The Oncologist 12 766-773
[6]
Willems A(2003)Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2972-2977
[7]
Geyer CE(2004)The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma Cancer 101 810-816
[8]
Forster J(2004)Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment Eur J Cancer 40 379-382
[9]
Lindquist D(2007)Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer Oncologist 12 1467-1469
[10]
Clayton AJ(2007)In reply Oncologist 12 1469-1471